NCT03342001

Brief Summary

Some people with hypothyroidism have persistent symptoms despite adequate treatment with thyroid hormones. We are testing whether giving calcitonin to such people will improve their quality of life.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jun 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 9, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 14, 2017

Completed
7 months until next milestone

Study Start

First participant enrolled

June 18, 2018

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 14, 2019

Completed
1.8 years until next milestone

Results Posted

Study results publicly available

June 10, 2021

Completed
Last Updated

February 21, 2022

Status Verified

February 1, 2022

Enrollment Period

1 year

First QC Date

November 9, 2017

Results QC Date

April 26, 2021

Last Update Submit

February 17, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Modified City of Hope Quality of Life Questionnaire for Patients With Thyroid Disease

    questionnaire to assess quality of life, 40 questions, 1-10 scale with 10 indicating more severe symptoms. Total 400 points, primary assessment was change in score after 6 weeks.

    6 weeks

Study Arms (1)

Treatment group, open label

EXPERIMENTAL

calcitonin nasal spray, 200 mcg daily

Drug: Calcitonin

Interventions

calcitonin nasal spray

Also known as: Miacalcin
Treatment group, open label

Eligibility Criteria

Age18 Years - 88 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Normal TSH on levothyroxine therapy

You may not qualify if:

  • pregnant or 6 months post partum
  • Current or previous thyroid cancer
  • Congenital hypothyroidism
  • any tobacco use
  • prescribed proton pump inhibitors
  • prescribed steroids
  • taking armour thyroid, naturethroid, or any dessicated thyroid hormone
  • Unstable medical conditions (CKD, Cirrhosis etc)
  • pituitary disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Maryland Center for Diabetes and Endocrinology

Baltimore, Maryland, 21201, United States

Location

Related Publications (1)

  • Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002 Nov;57(5):577-85. doi: 10.1046/j.1365-2265.2002.01654.x.

    PMID: 12390330BACKGROUND

MeSH Terms

Conditions

Hypothyroidism

Interventions

Calcitoninsalmon calcitonin

Condition Hierarchy (Ancestors)

Thyroid DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Peptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsThyroid HormonesNeuropeptidesPeptidesAmino Acids, Peptides, and ProteinsNerve Tissue ProteinsProteins

Results Point of Contact

Title
Dr. Kashif Munir
Organization
University of Maryland School of Medicine

Study Officials

  • Kashif Munir, M.D.

    University of Maryland

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

November 9, 2017

First Posted

November 14, 2017

Study Start

June 18, 2018

Primary Completion

June 30, 2019

Study Completion

August 14, 2019

Last Updated

February 21, 2022

Results First Posted

June 10, 2021

Record last verified: 2022-02

Data Sharing

IPD Sharing
Will not share

Locations